ThromboGenics Delays Diabetic Retinopathy Study; On Track To File Ocriplasmin For Retinal Adhesions
This article was originally published in The Pink Sheet Daily
Executive Summary
Belgian company focuses on filing orciplasmin for U.S. and EU approval, and preparing for commercialization.
You may also be interested in...
ThromboGenics Takes Its Time On Solo Launch Of Eye Drug Jetrea
Having taken a conservative approach to its first commercial launch, ThromboGenics plans to roll out newly approved eye drug Jetrea (ocriplasmin) in January 2013. Company is now recruiting a sales force to target retinal specialists, who are already well aware of the new drug.
Eyeing Solo U.S. Debut, EU Biotech ThromboGenics Preps Ocriplasmin For Launch
Small European biotechs usually build their business in their home region first, and later look to the US for growth. Belgium's ThromboGenics is doing the opposite; it aims to launch its lead product initially in the US, and will tackle Europe after partner and market leader Alcon paves the way.
Alcon Grabs Ex-U.S. Rights To ThromboGenics' Retina Adhesion Therapy Ocriplasmin In $500 Mil. Deal
Novartis' ophthalmic unit Alcon will collaborate with Belgium's ThromboGenics on the marketing and future development of the vitreomacular adhesion therapy, ocriplasmin.